Hetero is a research based global pharmaceutical company focused on development, manufacturing and marketing of Active Pharmaceutical Ingredients (APIs), Intermediate Chemicals & Finished Dosages. Ever since its establishment in 1993, Hetero showed a tradition of excellence and deep sense of commitment in developing cost effective processes to offer wide range of affordable drugs.
Hetero is building on the strengths of vertical integration in discovery research, process chemistry, API manufacturing, formulation development and commercialization.
Hetero exports its products across different regions – USA, Canada, Europe, Japan, Latin America, Middle East, Far East, Africa, Russia & CIS, Australia in the world and is catering to the requirements of around 138 countries in the world.
Research & Development is the foundation of Hetero’s philosophy
of developing cost-effective, high quality and safe medicines to society. Hetero Research Foundation (HRF) has a team of over 400 dedicated scientists.
- Hetero launches India’s one of the largest finished dosage manufacturing facility in Special Economic Zone (SEZ) at Jadcherla.
- Hetero receives tentative approval for Tenofovir disoproxil fumarate tablets from USFDA
